MannKind Corporation (NASDAQ:MNKD) will be hosting a conference call at 5:00 PM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.mannkindcorp.com
Earnings Expectation
MannKind Corporation is set to announce third quarter earning results on Wednesday 4th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, MNKD to report 3Q20 loss of $ 0.05 per share from revenue of $ 15.56 million. For the full year, analysts anticipate top line of $ 63.65 million, while looking forward to loss of $ 0.18 per share bottom line.
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension.
